Understand the source comparison
SS-LUP-332 Legal 2026 Status: Regulatory Comparison
DEA Scheduling None. Not a controlled substance None. Prescription required but not scheduled Schedule II. Strict prescribing limits SS-LUP-332 has no abuse potential classification; legal risk centers on unapproved human use, not possession FDA Approval Statu
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- DEA Scheduling
- None. Not a controlled substance
- None. Prescription required but not scheduled
- Schedule II. Strict prescribing limits
- SS-LUP-332 has no abuse potential classification; legal risk centers on unapproved human use, not possession
- FDA Approval Status
- No IND filed; preclinical stage only
- Full FDA approval for therapeutic indication
- N/A. Controlled via scheduling
- Compound cannot legally be marketed for human health claims without clinical trial data
- Legal Purchase for Research
- Yes. Through licensed suppliers with research documentation
- Prescription-only via licensed pharmacies
- DEA-registered pharmacies only
- Institutional researchers can procure SS-LUP-332; individuals claiming personal research use face legal ambiguity
- Marketing Restrictions
- Cannot be sold for human consumption
- Approved marketing for specific indications
- Prohibited outside medical use
- Suppliers labeling it "not for human use" comply with current law; mislabeling triggers FDA enforcement
- International Status
- Unregulated in most jurisdictions; varies by country
- Approved in U.S., EU, Canada for weight management
- Internationally controlled under UN conventions
- SS-LUP-332 legal 2026 status may differ outside the U.S.; importation rules vary